Beyond Air (XAIR): Customer Relationships and Revenue Channels

Beyond Air develops and commercializes nitric oxide (NO) generators and delivery systems under the LungFit platform and monetizes primarily by leasing its LungFit PH devices to hospitals and medical centers under fixed-fee arrangements. The company is a commercial-stage medical device seller with an active US commercialization effort, supplemental biopharma activity through the NeuroNOS subsidiary that was being marketed for divestiture, and distribution access accelerated by national group purchasing organization agreements. For investors, the core thesis is simple: device lease revenue and GPO access drive near-term commercial traction, while attempted asset sales and limited institutional penetration shape financing and runway dynamics. Learn more at Null Exposure.

How Beyond Air actually earns revenue and what that implies for investors

Beyond Air’s commercial model is device-first. The company’s LungFit PH obtained FDA premarket approval in mid-2022 and the firm recognizes revenue from device leases under fixed fee arrangements for periods up to three years, creating short-term recurring revenue rather than long-term capital sales. The most recent public statements indicate LungFit PH lease revenue of $3.7 million for the year ended March 31, 2025, up from $1.2 million the prior year, demonstrating early commercial momentum but still modest scale relative to cash burn.

Several structural signals matter when valuing XAIR:

• Contracting posture: short-term fixed-fee leases (up to three years) support revenue visibility over limited horizons but expose the business to churn and adoption cycles.
• Geography: primarily U.S.-focused commercialization, with explicit plans to expand a domestic sales and technical organization to reach hospitals capable of using NO.
• Relationship role: seller and direct marketer via field sales teams, which necessitates continued investment in commercial infrastructure and training.
• Segment profile: hardware-led revenue with clinical-stage biopharma assets; device sales/leasing constitute the immediate revenue engine while subsidiary assets offer optionality or non-dilutive financing via divestiture.

If you want a concise corporate snapshot and relationship model, visit Null Exposure.

Counterparties and what they mean for commercial traction

XTL Biopharmaceuticals Ltd.

Beyond Air entered into a January 2026 arrangement under which XTL agreed to acquire approximately 85% of NeuroNOS, Beyond Air’s subsidiary focused on ASD and neuro-oncology, for up to $32.5 million in cash, milestones and equity—a deal that market coverage credited with a sharp intraday move in XAIR shares. Source: CoinCentral coverage of the January 2026 announcement. Subsequent public notices, however, reported that the agreement to sell NeuroNOS to XTL was terminated in March 2026, removing an expected near-term source of proceeds and altering the company’s financing runway. Source: GlobeNewswire notice reported via The Manila Times, March 10, 2026.

Premier (PINC)

Beyond Air holds a national group purchasing organization agreement with Premier, which the company cites as part of its distribution strategy to reach hospitals. That GPO relationship is a commercial accelerant that expands access to ordering channels across U.S. hospitals. Source: public remarks in the FY2026 earnings call transcript.

Vizient

Beyond Air also has a national GPO agreement with Vizient, and combined with Premier the agreements provide access to nearly 3,000 U.S. hospitals—an important scale vector for device leasing and reimbursement conversations. Source: FY2026 earnings call transcript.

Vanderbilt University Medical Center

Beyond Air named Vanderbilt University Medical Center as its first luminary site for LungFit PH, positioning VUMC as a clinical and commercial reference center for adoption and clinician training. This relationship serves both as a commercial proof point and a clinician-confidence signal for hospital buyers. Source: Q4 FY2025 earnings call remarks.

What these relationships reveal about operating leverage and risks

The relationship set makes the company’s strategic posture clear: commercialize LungFit PH in the U.S. via direct sales and national GPO access while monetizing biopharma optionality through asset-level transactions. That model produces a distinct risk/reward profile:

• Revenue concentration and short contracting horizons. Revenue currently derives from device leases that run up to three years—this produces visible near-term revenue but limited long-term contractual lock-in, increasing sensitivity to adoption and reimbursement cycles.
• Distribution scale but reliance on payor acceptance. GPO agreements with Premier and Vizient materially improve market access, but ultimate utilization depends on hospitals’ reimbursement and internal formulary decisions; payor acceptance remains a gating factor for durable uptake.
• Commercial maturity is early but improving. The designation of Vanderbilt as a luminary site signals clinical validation and a pathway to broader hospital adoption; however, commercial scale is still modest relative to the total addressable hospital base.
• Balance sheet and financing implications from the NeuroNOS transaction arc. The announced XTL deal had been a potential source of up to $32.5 million in mixed consideration; its termination removes that immediate financing pathway and increases pressure on operational cash flow and capital markets access.

In short: the core business delivers tangible device revenue growth but requires continued capital or successful asset monetizations to reach self-sustaining scale. Explore deeper relationship analytics at Null Exposure.

Investment implications and closing takeaways

• Catalysts: scaling device leases through GPO channels and converting luminary site validation into repeatable hospital deployments; any renewed or alternative divestiture of NeuroNOS would materially alter runway calculus.
• Risks: short-term contracts, U.S.-only commercialization concentration, and the lost NeuroNOS proceeds after the XTL termination increase execution and financing risk in the near term.
• Valuation context: commercial traction is real but limited; investors should value the company as a hardware-led commercial-stage firm with biopharma optionality, not as a mature recurring-revenue medical device company.

For analysts and operators evaluating customer exposure, the combination of short-term leasing contracts, national GPO relationships, direct sales posture, and early luminary site adoption frames Beyond Air as a growth-stage device seller with meaningful upside if the company converts its hospital access into sustained utilization and secures replacement financing for the previously expected NeuroNOS proceeds.

To review source materials, model scenarios, or request a bespoke relationship analysis, visit Null Exposure.